Home Cart Sign in  
Chemical Structure| 496791-37-8 Chemical Structure| 496791-37-8

Structure of AR-C155858
CAS No.: 496791-37-8

Chemical Structure| 496791-37-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AR-C155858 is a selective inhibitor of monocarboxylate transporters MCT1 and MCT2, with Kis of 2.3 nM and 10 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Devin J. Seka ; Annika K. Schulz ; Tarjani M. Thaker ; Thomas M. Tomasiak ; ;

Abstract: The human Solute Carrier (SLC) family member, monocarboxylate transporter 1 (MCT1), transports lactic and across biological membranes to regulate cellular pH and metabolism. Proper trafficking of MCT1 from the endoplasmic reticulum to the plasma membrane hinges on its interactions with the membrane-bound chaperone protein, CD147. Here, using AlphaFold2 modeling and copurification, we show how a conserved signature motif located in the flexible N-terminus of MCT1 is a crucial region of interaction between MCT1 and the C-terminus of CD147. Mutations to this motif—namely the thymic cancer linked G19C and the highly conserved W20A—destabilize the MCT1-CD147 complex and lead to a loss of proper membrane localization and cellular substrate flux. Notably, the monomeric stability of MCT1 remains unaffected in mutants, thus supporting the role of CD147 in mediating trafficking of the heterocomplex. Using the auxiliary chaperone, GP70, we demonstrated that W20A-MCT1 can be trafficked to the plasma membrane, while G19C-MCT1 remains internalized. Overall, our findings underscore the critical role of the MCT1 transmembrane 1 signature motif for engaging CD147 and identify altered chaperone binding mechanisms between the CD147 and GP70 glycoprotein chaperones.

Keywords: Monocarboxylate transporters ; lactate ; pyruvate ; membrane complexes ; thermostability ; trafficking ; subcellular localization

Purchased from AmBeed:

Alternative Products

Product Details of AR-C155858

CAS No. :496791-37-8
Formula : C21H27N5O5S
M.W : 461.53
SMILES Code : O=C1N(CC(C)C)C2=C(C(C(N3OC[C@@H](O)C3)=O)=C(CC4=C(C)NN=C4C)S2)C(N1C)=O
MDL No. :MFCD22124476
InChI Key :ISIVOJWVBJIOFM-ZDUSSCGKSA-N
Pubchem ID :10226546

Safety of AR-C155858

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF-7 cells 20 μM 7 days Inhibition of MCT1/2 attenuated MCF-7 spheroid growth Mol Cancer. 2016 Jun 6;15(1):45
MCF-7 breast cancer cells 10 µM Evaluate the effect of AR-C155858 on cell growth. Results showed that AR-C155858 inhibited cell growth when lactate was the only available fuel but had no significant effect in the presence of glucose. Nat Commun. 2018 Mar 23;9(1):1208.
FaDu pharynx squamous cell carcinoma cells 10 µM Evaluate the effect of AR-C155858 on cell growth. Results showed that AR-C155858 inhibited cell growth when lactate was the only available fuel but had no significant effect in the presence of glucose. Nat Commun. 2018 Mar 23;9(1):1208.
SiHa cervix cancer cells 10 µM 72 h Evaluate the effect of AR-C155858 on cell growth in the presence of lactate or glucose. Results showed that AR-C155858 inhibited cell growth when lactate was the only available fuel but had no significant effect in the presence of glucose. Nat Commun. 2018 Mar 23;9(1):1208.
Ras-transformed fibroblasts CCL39-mct4 100 nM 10 days conferred resistance to MCT1/2 inhibition and reestablished tumorigenicty Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16663-8
Ras-transformed fibroblasts CCL39-ev 100 nM 10 days suppressed lactate export, glycolysis, and tumor growth Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16663-8
Polymorphonuclear neutrophils (PMN) 1 µM 30 min To investigate the effect of AR-C155858 on E. bovis sporozoite-induced NET formation. Results showed that AR-C155858 significantly reduced sporozoite-induced 'anchored' and 'cell-free' NET formation. Front Immunol. 2022 Aug 11;13:842482
retinal tissue 5 μM 40 min Test the effect of AR-C155858 on retinal succinate export, results showed it inhibited succinate export Invest Ophthalmol Vis Sci. 2022 Apr 1;63(4):1
Primary mouse cortical neurons 10 nM 30-120 min Inhibition of lactate uptake to model localized nutrient deprivation, leading to increased AMPK phosphorylation and subsequent suppression of mitochondrial transport J Neurosci. 2020 Jun 17;40(25):4798-4812
human HCC1937 breast cancer cells 200 nM 30 min To confirm the reversibility of AR-C155858 inhibition on L-lactate uptake in HCC1937 cells, showing slow reversibility of inhibition. AAPS J. 2019 Jan 7;21(2):13
murine 4T1 breast tumor cells 200 nM 5 min To evaluate the inhibitory effect of AR-C155858 on L-lactate uptake, showing maximal inhibition after 5-min pre-incubation and prolonged inhibition. AAPS J. 2019 Jan 7;21(2):13
4T1 cells 25.0 ± 4.2 nM (IC50) 48 h To evaluate the inhibitory effect of AR-C155858 on L-lactate uptake and cell proliferation in 4T1 cells. Results showed that AR-C155858 effectively inhibited L-lactate uptake and cell proliferation. AAPS J. 2018 Nov 5;21(1):3

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/SCID mice B-cell leukemia xenograft model Intraperitoneal injection 5 mg/kg Daily for 12 days To evaluate the antitumor effect of MCT-1 inhibition combined with CAR T cell therapy, results showed significant reduction in tumor burden. J Immunother Cancer. 2023 Jun;11(6):e006287.
Nude mice Ras-transformed fibroblasts CCL39-ev and CCL39-mct4 Subcutaneous injection 30 mg/kg Twice daily for 6 days Suppressed tumor growth, CCL39-ev tumors did not develop during treatment, CCL39-mct4 tumors were insensitive to inhibition Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16663-8
NMRI nude mice SiHa tumor xenografts Intraperitoneal injection 3 mg/kg Once daily for 9 days Evaluate the effect of AR-C155858 on tumor growth. Results showed that AR-C155858 had a significantly weaker inhibitory effect on tumor growth compared to 7ACC2. Nat Commun. 2018 Mar 23;9(1):1208.
BALB/c mice 4T1 breast cancer xenograft model Intraperitoneal injection 10 mg/kg Once daily for 28 days To evaluate the in vivo efficacy of AR-C155858 in the 4T1 breast cancer xenograft model. Results showed that AR-C155858 had no significant effect on tumor volume and weight, but tumor drug concentrations were significantly higher than blood concentrations. AAPS J. 2018 Nov 5;21(1):3
Sprague-Dawley rats GHB and ketamine co-administration model Intravenous injection 1 mg/kg Single dose To evaluate the effect of AR-C155858 on GHB toxicokinetics and toxicodynamics, results showed that AR-C155858 significantly increased GHB renal and total clearance and improved respiratory depression Pharmaceutics. 2021 May 18;13(5):741

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.83mL

2.17mL

1.08mL

21.67mL

4.33mL

2.17mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories